STOCK TITAN

Orthopedia Stock Price, News & Analysis

KIDS NASDAQ

Company Description

OrthoPediatrics Corp. (NASDAQ: KIDS) is an orthopedic medical device company focused exclusively on advancing the field of pediatric orthopedics. Founded in 2006, the company develops and markets implants, instruments, and specialty bracing systems designed specifically to address orthopedic conditions in children and adolescents. According to company disclosures, OrthoPediatrics has developed a broad product offering for the pediatric orthopedic market and reports having helped hundreds of thousands of children with orthopedic conditions since its inception.

OrthoPediatrics states that it serves three of the largest categories within the pediatric orthopedic market: trauma and deformity, scoliosis, and sports medicine/other procedures. Its trauma and deformity portfolio includes systems designed for fracture management and deformity correction in growing patients. The scoliosis portfolio includes implant and instrument systems for complex spinal deformities in children, including early onset scoliosis. Sports medicine and other procedure offerings support additional pediatric orthopedic interventions.

Business focus and product portfolio

The company describes itself as having developed what it calls the most comprehensive product offering for pediatric orthopedic surgeons. OrthoPediatrics reports that it currently markets over 80 product systems, and in some disclosures references more than 85 products, across its core categories. These systems include plates, screws, intramedullary nails, spinal implants, and related instruments designed for pediatric anatomy, as well as specialty bracing products through its OrthoPediatrics Specialty Bracing ("OPSB") division.

Within trauma and deformity, OrthoPediatrics highlights products such as the 3P Pediatric Plating Platform family, including the 3P Hip System and the 3P Pediatric Plating Platform Small-Mini System. The 3P Small-Mini System is described as a plate and screw solution with variable-angle locking implants, procedure-specific and utility plates, and specialized instruments aimed at supporting a wide range of pediatric trauma and deformity surgeries. The company also notes that its portfolio includes trauma and deformity plates, screws, intramedullary nails, and related instruments.

In scoliosis, OrthoPediatrics references its Response Spine systems and the VerteGlide Spinal Growth Guidance System. VerteGlide is described as a scoliosis deformity correction system for early onset scoliosis patients that leverages implant and instrument technology and incorporates Shilla technology licensed from Medtronic. The company positions VerteGlide as an option for some of the most complex pediatric spinal pathologies. OrthoPediatrics also notes that its scoliosis suite includes other systems designed for spinal deformity correction in children.

The OPSB division expands the company’s presence in non-surgical and post-surgical care. OrthoPediatrics reports that OPSB offers a growing portfolio of specialty bracing products and services, including hip bracing systems such as the PediHip Rigid Brace and PediHip Modular Abduction System. These braces are described as intended for the treatment of Developmental Dysplasia of the Hip (DDH) and post-operative stabilization in pediatric patients three years of age and younger. The company has also disclosed that OPSB clinics are an area of ongoing growth.

Market reach and distribution

OrthoPediatrics’ disclosures state that its global sales organization is focused exclusively on pediatric orthopedics. The company reports distributing its products in the United States and in more than 70 countries outside the United States. This international footprint supports the use of its trauma and deformity, scoliosis, sports medicine, and specialty bracing systems in a wide range of pediatric orthopedic practices.

The company is incorporated in Delaware and, based on SEC filings, maintains its principal operations in Warsaw, Indiana. OrthoPediatrics’ common stock trades on the Nasdaq Stock Market under the ticker symbol KIDS. SEC filings indicate that the company files periodic reports, including quarterly and annual financial statements, and uses Form 8-K to report material events such as earnings releases, guidance updates, and changes in its board of directors.

Clinical and technology collaborations

OrthoPediatrics highlights collaboration with pediatric orthopedic surgeons and clinical experts in the development of its products. For example, the PediHip Rigid Brace and PediHip Modular Abduction System were developed in collaboration with pediatric hip experts. The VerteGlide Spinal Growth Guidance System is based on Shilla technology licensed from Medtronic, reflecting a licensing relationship for specific scoliosis technology. The company also notes that its products are featured at specialty meetings focused on scoliosis and early onset scoliosis.

In addition to internal product development, OrthoPediatrics has disclosed a distribution partnership with MY01 Inc. Through this collaboration, OrthoPediatrics distributes MY01’s Continuous Perfusion Sensing Technology (CPST) platform for the diagnosis of limb perfusion injuries, including acute compartment syndrome, in children and adolescents. The company presents this partnership as an extension of its focus on pediatric trauma care and medical education.

Regulatory milestones and product approvals

OrthoPediatrics reports multiple regulatory milestones for its systems. The company has announced U.S. Food and Drug Administration (FDA) approval for the 3P Pediatric Plating Platform Small-Mini System, describing it as the second system in the 3P family and noting that it was one of several FDA approvals received in a single year. It has also reported receiving European Union Medical Device Regulation (EUMDR) certification for certain spine, trauma, and deformity implants and instruments, including Response Spine systems and various plates, screws, and intramedullary nails.

These regulatory clearances and certifications are presented by the company as enabling broader clinical use of its systems in pediatric orthopedic surgery and as part of its ongoing product development and commercialization efforts.

Financial and operational disclosures

Through its public news releases and SEC filings, OrthoPediatrics provides information on revenue trends, adjusted EBITDA, and free cash flow usage. The company has reported year-over-year revenue growth and has highlighted contributions from its Trauma and Deformity, Scoliosis, and OPSB product lines. It has also discussed restructuring activities, intangible asset impairments, and initiatives aimed at improving operational efficiency and reducing operating costs. While specific financial figures are time-sensitive and subject to change, these disclosures illustrate the company’s focus on scaling its pediatric orthopedic platform and managing its cost structure.

OrthoPediatrics frequently emphasizes the number of children treated with its products as a key measure of impact. In recent communications, it has referenced having helped approximately 1.3 million children since inception, and tens of thousands of children in individual quarters.

Corporate governance and investor relations

The company’s SEC filings document changes in its board of directors and executive leadership. For example, OrthoPediatrics has reported the retirement of a long-serving director and the appointment of a new board member with experience in financial leadership at a large medical device company. The company also regularly participates in healthcare and investor conferences, where its executive officers present to investors and analysts using materials furnished via Form 8-K.

OrthoPediatrics uses press releases and webcasts to communicate quarterly results, preliminary revenue updates, and financial guidance. These communications are often furnished as exhibits to Form 8-K, providing investors with access to unaudited financial data and management commentary on business performance, guidance updates, and strategic priorities.

Position within pediatric orthopedics

Across its public communications, OrthoPediatrics consistently describes itself as focused exclusively on pediatric orthopedics, with a product offering spanning trauma and deformity, scoliosis, sports medicine/other procedures, and specialty bracing. The company highlights its global sales organization, surgeon collaborations, and product development efforts as central to its role in the pediatric orthopedic market. Its disclosures emphasize both implant-based surgical solutions and non-implant offerings such as bracing and diagnostic partnerships, all directed toward improving care for children with orthopedic conditions.

Stock Performance

$16.47
-0.30%
0.05
Last updated: March 23, 2026 at 16:00
-33.75%
Performance 1 year
$417.6M

Orthopedia (KIDS) stock last traded at $16.47, down 0.30% from the previous close. Over the past 12 months, the stock has lost 33.8%. At a market capitalization of $417.6M, KIDS is classified as a small-cap stock with approximately 25.3M shares outstanding.

Latest News

Orthopedia has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include earnings, earnings date, conferences, fda approval. View all KIDS news →

SEC Filings

Orthopedia has filed 5 recent SEC filings, including 5 Form 4. The most recent filing was submitted on March 17, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all KIDS SEC filings →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
58,171
Shares Sold
5
Transactions
Most Recent Transaction
Bailey David R (President and CEO) sold 19,535 shares @ $17.25 on Mar 16, 2026

Insider selling at Orthopedia over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

$236.3M
Revenue (TTM)
-$39.6M
Net Income (TTM)
-$4.9M
Operating Cash Flow

Orthopedia generated $236.3M in revenue over the trailing twelve months, retaining a 73.0% gross margin, operating income reached -$39.2M (-16.6% operating margin), and net income was -$39.6M, reflecting a -16.8% net profit margin. Diluted earnings per share stood at $-1.69. The company generated -$4.9M in operating cash flow. With a current ratio of 5.55, the balance sheet reflects a strong liquidity position.

Upcoming Events

Short Interest History

Last 12 Months

Short interest in Orthopedia (KIDS) currently stands at 991.0 thousand shares, down 2.1% from the previous reporting period, representing 5.8% of the float. The 7.8 days to cover indicates moderate liquidity for short covering.

Days to Cover History

Last 12 Months

Days to cover for Orthopedia (KIDS) currently stands at 7.8 days, up 52.8% from the previous period. This moderate days-to-cover ratio suggests reasonable liquidity for short covering, requiring about a week of average trading volume. The ratio has shown significant volatility over the period, ranging from 3.9 to 12.2 days.

KIDS Company Profile & Sector Positioning

Orthopedia (KIDS) operates in the Medical Devices industry within the broader Surgical & Medical Instruments & Apparatus sector and is listed on the NASDAQ.

Investors comparing KIDS often look at related companies in the same sector, including ZIMVIE INC (ZIMV), Treace Medical Concepts, Inc. (TMCI), Cytek Biosciences, Inc. (CTKB), STANDARD BIOTOOLS INC (LAB), and Bioventus Inc. (BVS). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate KIDS's relative position within its industry.

Frequently Asked Questions

What is the current stock price of Orthopedia (KIDS)?

The current stock price of Orthopedia (KIDS) is $16.47 as of March 23, 2026.

What is the market cap of Orthopedia (KIDS)?

The market cap of Orthopedia (KIDS) is approximately 417.6M. Learn more about what market capitalization means .

What is the revenue (TTM) of Orthopedia (KIDS) stock?

The trailing twelve months (TTM) revenue of Orthopedia (KIDS) is $236.3M.

What is the net income of Orthopedia (KIDS)?

The trailing twelve months (TTM) net income of Orthopedia (KIDS) is -$39.6M.

What is the earnings per share (EPS) of Orthopedia (KIDS)?

The diluted earnings per share (EPS) of Orthopedia (KIDS) is $-1.69 on a trailing twelve months (TTM) basis. Learn more about EPS .

What is the operating cash flow of Orthopedia (KIDS)?

The operating cash flow of Orthopedia (KIDS) is -$4.9M. Learn about cash flow.

What is the profit margin of Orthopedia (KIDS)?

The net profit margin of Orthopedia (KIDS) is -16.8%. Learn about profit margins.

What is the operating margin of Orthopedia (KIDS)?

The operating profit margin of Orthopedia (KIDS) is -16.6%. Learn about operating margins.

What is the gross margin of Orthopedia (KIDS)?

The gross profit margin of Orthopedia (KIDS) is 73.0%. Learn about gross margins.

What is the current ratio of Orthopedia (KIDS)?

The current ratio of Orthopedia (KIDS) is 5.55, indicating the company's ability to pay short-term obligations. Learn about liquidity ratios.

What is the gross profit of Orthopedia (KIDS)?

The gross profit of Orthopedia (KIDS) is $172.7M on a trailing twelve months (TTM) basis.

What is the operating income of Orthopedia (KIDS)?

The operating income of Orthopedia (KIDS) is -$39.2M. Learn about operating income.

What does OrthoPediatrics Corp. do?

OrthoPediatrics Corp. is an orthopedic medical device company focused exclusively on pediatric orthopedics. It develops and markets implants, instruments, and specialty bracing systems designed to treat orthopedic conditions in children and adolescents, spanning trauma and deformity, scoliosis, and sports medicine or other procedures.

When was OrthoPediatrics founded?

According to the company’s public disclosures, OrthoPediatrics was founded in 2006 as an orthopedic company dedicated to advancing the field of pediatric orthopedics.

In which markets does OrthoPediatrics operate?

OrthoPediatrics states that its global sales organization focuses exclusively on pediatric orthopedics and distributes its products in the United States and in more than 70 countries outside the United States.

What are the main product categories for OrthoPediatrics?

The company reports that its product offering spans three of the largest categories within the pediatric orthopedic market: trauma and deformity, scoliosis, and sports medicine/other procedures. It also offers specialty bracing products through its OrthoPediatrics Specialty Bracing division.

What is the OrthoPediatrics Specialty Bracing (OPSB) division?

The OPSB division is OrthoPediatrics’ specialty bracing business. The company states that OPSB offers a portfolio of braces and related services, including products such as the PediHip Rigid Brace and PediHip Modular Abduction System, and that OPSB clinics are an area of ongoing growth.

What is the VerteGlide Spinal Growth Guidance System?

VerteGlide is described by OrthoPediatrics as a spinal growth guidance system within its scoliosis product suite, used to treat early onset scoliosis. It is presented as a deformity correction system for complex pediatric spinal pathology and incorporates Shilla technology licensed from Medtronic.

What is the 3P Pediatric Plating Platform?

The 3P Pediatric Plating Platform is a family of plating systems that OrthoPediatrics has developed for pediatric trauma and deformity surgeries. The company has highlighted the 3P Hip System and the 3P Pediatric Plating Platform Small-Mini System, which includes variable-angle locking plates and specialized instruments designed for pediatric orthopedic surgeons.

On which exchange does OrthoPediatrics stock trade and what is its ticker?

OrthoPediatrics’ common stock trades on the Nasdaq Stock Market under the ticker symbol KIDS, as indicated in the company’s news releases and SEC filings.

How many products does OrthoPediatrics market?

In its public communications, OrthoPediatrics reports that it currently markets over 80 product systems, and in some cases more than 80 or 82 systems, across trauma and deformity, scoliosis, and sports medicine/other procedures, along with specialty bracing offerings.

How does OrthoPediatrics measure its impact on patients?

The company often cites the number of children treated with its products as a measure of impact. In recent disclosures, OrthoPediatrics has reported having helped approximately 1.3 million children since inception and tens of thousands of children in individual quarters.